Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Dr. Robert C. Martin

Surgical Oncology | General Surgery
University Of Louisville Physicians Inc
401 E Chestnut St, Suite 710, 
Louisville, KY 
Accepting New Patients
Offers Telehealth
Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
University Of Louisville Physicians Inc
401 E Chestnut St, Suite 710, 
Louisville, KY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Martin is a Surgical Oncologist and a General Surgeon in Louisville, Kentucky. Dr. Martin is rated as an Experienced provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Pancreatic Cancer, Liver Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatectomy, and Hepatectomy. Dr. Martin is currently accepting new patients.

His clinical research consists of co-authoring 372 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Surgical Oncology
General Surgery
Licenses
Surgery in KY
Hospital Affiliations
University Of Louisville Hospital
Norton Hospitals, Inc
UOFL HEALTH - JEWISH HOSPITAL And Mary & Elizabeth Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

UNIVERSITY OF LOUISVILLE PHYSICIANS INC
401 E Chestnut St, Suite 710, Louisville, KY 40202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drug: ZW25 (Zanidatamab)
Study Phase: Phase 2
Comparative, Prospective, Open-labeled, Randomized Phase II Study of Cisplatin or Carboplatin With Gemcitabine in Combination With Irinotecan-loaded Beads (LC or ONCOZENE) Versus Cisplatin or Carboplatin With Gemcitabine Alone in the Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Comparative, Prospective, Open-labeled, Randomized Phase II Study of Cisplatin or Carboplatin With Gemcitabine in Combination With Irinotecan-loaded Beads (LC or ONCOZENE) Versus Cisplatin or Carboplatin With Gemcitabine Alone in the Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Enrollment Status: Completed
Publish Date: February 27, 2025
Intervention Type: Drug, Device
Study Phase: Phase 2
Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage 3 Pancreatic Adenocarcinoma
Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage 3 Pancreatic Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2025
Intervention Type: Drug, Device
The Effect of FOLFIRINOX and Stereotactic Body Radiation Therapy for Locally Advanced, Non-Resectable Pancreatic Cancer
The Effect of FOLFIRINOX and Stereotactic Body Radiation Therapy for Locally Advanced, Non-Resectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Radiation, Drug
Study Drug: Folfirinox
Study Phase: Phase 2
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
Enrollment Status: Unknown
Publish Date: March 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
Enrollment Status: Completed
Publish Date: November 08, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 19, 2022
Intervention Type: Drug, Procedure
Study Drugs: Fluorouracil, Gemcitabine hydrochloride, Irinotecan hydrochloride, Oxaliplatin, Paclitaxel albumin-stabilized nanoparticle formulation
Study Phase: Phase 2
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Drug, Procedure, Radiation
Study Drugs: mFOLFIRINOX, FOLFOX
Study Phase: Phase 2
A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
Enrollment Status: Completed
Publish Date: March 29, 2022
Intervention Type: Device
Study Phase: Not Applicable
Louisville Cooperative Tissue Biorepository of the James Graham Brown Cancer Center Tissue Collection Consent
Louisville Cooperative Tissue Biorepository of the James Graham Brown Cancer Center Tissue Collection Consent
Enrollment Status: Completed
Publish Date: November 10, 2021
A Randomized Controlled Trial of Transcatheter Arterial Chemoembolization With Drug Eluting Beads (DEB-TACE) Versus Sorafenib in the Treatment of Unresectable, Locally Advanced Hepatocellular Carcinoma
A Randomized Controlled Trial of Transcatheter Arterial Chemoembolization With Drug Eluting Beads (DEB-TACE) Versus Sorafenib in the Treatment of Unresectable, Locally Advanced Hepatocellular Carcinoma
Enrollment Status: Terminated
Publish Date: February 12, 2021
Intervention Type: Device, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
Enrollment Status: Completed
Publish Date: December 16, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 3
A Phase III, Multicenter, Open-Label, Randomized Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablated Intra-Hepatic Cholangiocarcinoma
A Phase III, Multicenter, Open-Label, Randomized Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablated Intra-Hepatic Cholangiocarcinoma
Enrollment Status: Withdrawn
Publish Date: February 19, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 12 Less Clinical Trials

372 Total Publications

A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity.
A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity.
Journal: bioRxiv : the preprint server for biology
Published: August 12, 2025
Similar Doctors
Charles R. Scoggins
Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Charles R. Scoggins
Surgical Oncology | General Surgery
Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Charles R. Scoggins
Surgical Oncology | General Surgery

University Of Louisville Physicians Inc

401 E Chestnut St, Suite 710, 
Louisville, KY 
 (0.1 miles away)
502-583-8303
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Charles Scoggins is a Surgical Oncologist and a General Surgeon in Louisville, Kentucky. Dr. Scoggins is rated as an Elite provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Gallbladder Cancer, Gallbladder Disease, Hepatectomy, and Pancreatectomy. Dr. Scoggins is currently accepting new patients.

Prejesh A. Philips
Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Prejesh A. Philips
Surgical Oncology
Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Prejesh A. Philips
Surgical Oncology

University Of Louisville Physicians Inc

401 E Chestnut St, Suite 710, 
Louisville, KY 
 (0.1 miles away)
502-583-8303
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Prejesh Philips is a Surgical Oncologist in Louisville, Kentucky. Dr. Philips is rated as an Advanced provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Familial Pancreatic Cancer, Familial Colorectal Cancer, Liver Cancer, Hepatectomy, and Pancreatectomy. Dr. Philips is currently accepting new patients.

Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Alberto S. Gallo
General Surgery
Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Alberto S. Gallo
General Surgery

Baptist Health Medical Group Inc

3950 Kresge Way, 
Louisville, KY 
 (5.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alberto Gallo is a General Surgeon in Louisville, Kentucky. Dr. Gallo is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Hernia, Retroperitoneal Inflammation, Ogilvie Syndrome, Sleeve Gastrectomy, and Gastric Bypass. Dr. Gallo is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Martin's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 23 Advanced Conditions
View All 61 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile